Harvard Scientific Corporation and Subsidiaries




Balance Sheet




September 30, 2001














ASSETS









CURRENT ASSETS




 Cash

 $
(47,730.82)


 Inventory


1,310.39


 Employee Advances


400.00


 Total Current Assets


 $
(46,020.43
)






 FIXED ASSETS




 Furniture & Fixtures


16,001.09


 Leasehold Improvements


21,400.00


 Total Fixed Assets



37,401.09






 OTHER ASSETS




 Capital Investment


22,205.00


 Deposits


815.00


 Total Other Assets



23,020.00






 Total Assets


 $
14,400.66











 LIABILITIES & EQUITY









 CURRENT LIABILITIES




 Accounts Payable

 $
160,077.15


 Payroll Liabilities


21,597.60


Credit Card Payable


723.17


 Total Current Liabilities



$182,397.
92






 LONG-TERM LIABILITIES




Loan to Shareholder

4,326.49


Note Payable-Pyramid Labs


133,100.00


Loan Payable


500.00


Loan Payable - GPA


42,225.00


Loan Payable - Ideas


94,058.00


 Total Long-Term Liabilities



274,209.4
9






 EQUITY




Common Stock


158,974.37


Paid-In-Capital


13,302,684.
65


Retained Earnings


(13,689,788.
45)


Net Loss (Jan '01 - Jun '01)


(179,498.52)


Net Loss (Jul '01 - Sep '01)


(34,578.80)


Total Equity



(442,206.7
5)






 Total Liabilities & Equity


 $
14,400.66






Harvard Scientific Corporation and Subsidiaries






Statement of Income






For the Three Months Ended July 01, 2001 through September 30,
2001



























REVENUES






Sales





 $ 31,136.25














COST OF GOOD
SOLD






Beverages




 $7,911.95

Restaurant Supplies




   2,323.32

Food




   4,931.10








Total Cost of Goods Sold





    15,166.37







Gross Profit





    15,969.88














EXPENSES






Automobile




         5.00

Bank Service Charges




   2,013.33

Cash Discounts




      650.00

Equipment Rental




      511.59

Insurance




   1,957.62

Interest Expense




       84.24

Office Expense




   1,459.68

Miscellaneous




   2,328.00

Music & Entertainment




   3,471.58

Printing & Reproduction




      190.00

Rent




      300.00

Repairs & Maintenance




   2,085.66

Telephone




      500.00

Travel & Entertainment




      533.62

Utilities




   6,863.43

Office Supplies




      137.94

Salaries & Wages




 25,883.93

Payroll Taxes




   1,573.06








Total Expense





    50,548.68







Net Loss





 $(34,578.80)







                            HARVARD SCIENTIFIC CORP.

                          (A DEVELOPMENT STAGE COMPANY)

                     NOTES TO THE FINANCIAL STATEMENTS Based
       on Audited Financial Statements at December 31, 2000, 1998
and
1999


NOTE 1 - NATURE OF BUSINESS AND ORGANIZATION

Nature of Business:
The company shifted from an exclusive biopharmaceutical drug
development company
to an Entertainment  Conglomerate.  The Company will eventually
further develop
its  biopharmaceutical  products  under  a  separate  name  and
company,  to be
determined at a later date.  The focus of the  Company's  activity
over
the next
twelve months will be to further  develop,  produce and
distribute the
existing
projects in the  Company's  recently  acquired  wholly owned
subsidiaries.  The
Company  and its  new  management  are  currently  in the  process
of
securing
sufficient  capital to satisfy  all of the  company's  outstanding
debts.  This
capital  may come in the form of a loan,  selling  off of  assets
of
the  newly
acquired  subsidiaries  or a personal loan from the officers and
directors  (See
note 11).

Organization:
The  Company was  incorporated  under the laws of the State of
Nevada
on January
13, 1987.  Effective  February 2, 1998, the Company  approved a 1
for
10 reverse
stock split.  Shares  outstanding  went from  34,477,437  on
February
1, 1998 to
3,447,769  just after the split.  The Company is moving forward
with a
strategic
plan to  facilitate  marketing of its  products in a manner which
is
consistent
with enhancing its corporate image and further increasing
shareholder
value. All
figures in this  Report give  effect to  previous  stock  splits
and
the reverse
stock splits, and previously stated number of shares is
appropriately
restated.
The Company has 100,000,000 shares of Common Stock authorized.  In
addition,  on
July 9, 1998, the shareholders of the Company  authorized
10,000,000
shares of
"blank check" Preferred  Stock,  none are outstanding on December
31,
2000, 1999
or 1998.


NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organizational Costs:
Organization  costs  are  being  amortized  over a  five-year
period
using the
straight-line  method. At December 31, 1999, the Organizational
Costs
were fully
amortized.

Inventory:
Inventory is valued at the lower of cost or market.

Equipment:
Equipment is stated at cost.  Depreciation is incorporated on a
double
declining
balance basis over a period of 5 years. Expenditures for
maintenance
and repairs
are charged to expense as incurred.  Upon retirement or disposal
of
assets,  the
cost and  accumulated  depreciation  are  eliminated  from the
accounts and any
resulting gain or loss is included in expense.

Use of Estimates:
In order to prepare  the  financial  statements  in  conformity
with
generally
accepted accounting  principles,  management must make estimates
and
assumptions
that affect  certain  reported  accounts and  disclosures.  Actual
results could
differ from these estimates.

Intellectual Properties:
The costs of  intellectual  properties  are  amortized  using the
straight-line
method over a period of fifteen years.

Earnings per share:
The earnings per share calculations were based on the weighted
average
number of
shares outstanding during the period.

Fully  dilutive   earnings  per  share  are  not  reflected
because
they  are
anti-dilutive.

Income Tax:
Because of losses  sustained  since  inception,  no provision  has
been
made for
income tax.

NOTE 3 - EQUIPMENT & LEASEHOLD IMPROVEMENTS

Equipment and building improvements consists of the following:

                                            December 31, 1998
Equipment & Leasehold Improvements          $       45,299
Less:  Accumulated depreciation                     35,461
                                            --------------
                            Total           $        9,838
                                            ==============

The  Company  had  incurred  leasehold  improvements  to the
Irvine
office  of
approximately $4,300 in 1997, amortized over the life of the
lease. In
May 1998,
the Company  terminated the Irvine lease and moved the research
and
development
office  from  Irvine to Costa  Mesa,  California.  The  balance
of
unamortized
improvements of approximately $2,755 was written off.

During the fourth  quarter of 1998 and the first  quarter of 1999,
the
Company
closed three  offices  (Florida,  Arizona and  California)  with
all
operations
maintained out of a Reno,  Nevada office.  The office equipment in
these offices
were donated to charitable organizations

                                       6
<PAGE>

NOTE 4 - INTELLECTUAL PROPERTIES

On January 7, 1994,  the Company  exchanged  285,600 shares of
common
stock with
BTI for the intellectual rights to patent, develop,  manufacture,
and
market the
LLPGE1 for the  treatment of male  erectile  dysfunction,
impotency
and sexual
enhancement. The Company recorded the transfer of intellectual
properties at the
par value of stock transferred, which amounted to $2,856.

On November 16, 1995, the Company  exchanged 613,850 shares of
common
stock with
BTI for assistance in raising  working  capital and patent
application
and for
management  assistance and  distribution  agreements  associated
with
the LLPGE1
product.   The  Company  recorded  the  transfer  at  the  par
value
of  stock
transferred, which amounted to $6,139.

During 1996, the Company expensed the unamortized  cost of
acquiring
technology
relating  to the  development  of an HIV  home  test  kit.  The
Company,  which
originally  acquired the rights in exchange for 33,500  shares of
common  stock,
ceased product development in connection with a settlement,
accrued in
1995.

During 1997, the Company entered into three additional significant
transactions
with BTI for the  acquisition of intellectual  rights,  and for
the
provision of
technological, management, fundraising and marketing assistance.
In
addition, in
1996,  the Company  incurred costs payable to BTI for
consultation
and rent of
$133,157 and for research and development $50,378 of the LLPGE1
product.  During
1997,  BTI chose to  convert  the  accounts  payable  balance of
$333,535  as a
contribution to additional-paid-in-capital.

On November 20, 1997,  the Company  agreed to exchange  200,000
shares
of common
stock,  which has been issued,  to BTI for the  Intellectual
Property
Rights to
Prostaglandin E1 Lyophilized Liposomes for the use of treatment of
Psoriasis. In
addition,  the Company is to pay BTI $150,000.  BTI was to receive
a 3%
override
on royalties of the  Psoriasis  product.  On June 11, 1998,  BTI
and
the Company
agreed  that BTI would  transfer  an  irrevocable  royalty-free
license  to all
intellectual property,  intangibles,  patents, trade secrets,
trademarks, trade
names and goodwill relating to BTI that exists or is in
development,
relating to
male  and/or  female  sexual  dysfunction,  for the  return of the
intellectual
property related to the Psoriasis product that BTI previously had
transferred to
the Company and the granting to BTI registration right (effective
July
28, 1998)
as to all shares of the Company's  common stock held by BTI on
July
20th,  1998.
In addition,  all royalty  agreements with respect to products
other
than sexual
dysfunction  have  been  terminated.   In  addition,  the  Company
forgave  the
indebtedness of BTI of $892,819.  The debt forgiveness is treated
as
part of the
cost of the intellectual properties received from BTI.

In  December  1998,  the  Company had a balance in  Intellectual
Properties  of
$1,053,814, with accumulated depreciation of $53,196 for a net of
$1,000,619. On
December  31,  1998,  Intellectual  Properties  was  written  down
to
zero,  the
determined market value at that time.

NOTE 5 - ACCRUED EXPENSES

Accrued expenses consist of the following:


                                            (Audited)
(Audited)
                                         December 31, 2000
December
31, 1998
                                         -----------------    ----
-----
--------
Interest on notes and debentures         $          23,763    $
-0-
Accrued payroll & payroll taxes                        -0-
63,662
                                         -----------------    ----
-----
--------

        Total                            $         23,763     $
63,662
                                         =================
=================

NOTE 6- NOTES PAYABLE

At December 31, 2000, Notes payable consists of the following:

                 Note Holder                        Amount
                 -----------                        ------
                 Snell                            $     500
                 Hidden Splendor                     25,000
                 Medhat Gorgy                        65,000
                 Pyramid Laboratories               133,100
                                                  ---------

                   Total                          $ 223,600
                                                  =========

                                       7
<PAGE>

NOTE 7 - RELATED PARTY TRANSACTIONS

1.   During  1997,  the  Company  incurred a payable of  $150,000
to
BTI for the
     Intellectual  Property Rights to Prostaglandin E1 Lyophilized
Liposomes for
     the use of treatment of  Psoriasis.  On June 11, 1998,  BTI
and
the Company
     agreed that BTI would transfer an irrevocable  royalty-free
license to all
     its intellectual property relating to sexual dysfunction, for
the
return of
     the  intellectual  property  related to the Psoriasis and
other
non-sexual
     dysfunction products that BTI previously had transferred.  In
addition, the
     Company forgave BTI's  indebtedness of $895,819,  which was
treated as part
     of the basis of the intellectual properties.

2.   During 1996, BTI advanced  20,000 of its shares on behalf of
the
Company as
     a subordinated  loan agreement.  The shares were loaned and
are
expected to
     be returned  to BTI in 1998.  At the time of the  advance,
the
fair market
     value of the shares  transferred  was  $500,000.  During
1997,
the Company
     advanced to BTI $500,000 in connection with this  settlement.
The
$500,000
     was part of the forgiven debt of $895,819 described above.

3.   In 1997, BTI, a major  stockholder of the Company,  received
$352,305 from
     the sale of the Company's Common Stock that was subject to
recapture by the
     Company pursuant to Section 16(b) of the Securities Exchange
Act
of 1934.

     In January 1998, BTI received $40,514 from the sale of the
Company's Common
     Stock that was subject  recapture by the Company  pursuant to
Section 16(b)
     of the Securities Exchange Act of 1934. In January 1998,
$40,514
was booked
     as a receivable from related parties to reflect the
recapture.
This amount
     was also part of the forgiven debt of $895,819 described
above.

4.   The Company has entered into a financing  agreement dated
January
13, 1998,
     as amended on February 3, 1998,  between Dr. Jackie R. See,
Thomas
E. Waite
     and the  Company  for the  funding of the  Company up to
$10,000,000.  Dr.
     Jackie R. See and Mr. Thomas E. Waite were Directors of the
Company. Thomas
     E. Waite was also President and Chief Executive Officer of
the
Company.  On
     February 3, 1998, the Company issued 790,139 shares to each
Dr.
Jackie See,
     M.D. and Thomas E. Waite in  connection  with this private
placement.  All
     shares  owned by Dr.  Jackie See and  Thomas E.  Waite,  have
registration
     rights.  These  registration  rights  have  been  exercised
and
upon  the
     registration  statement  becoming effective (July 28, 1998),
the
shares can
     be sold in accordance  with the  Securities  Act of 1933,
subject
to state
     securities laws. See Note 8 and Note 9.

5.   The Company often pays for services,  fees,  and salaries by
issuing shares
     of Common  Stock.  Most of this stock issued for services
must be
held for
     investment to satisfy the exemption from registration under
Section 4(2) of
     the Securities Act of 1933, as amended. Rule 144 under the
statute
requires
     that such  stock be held for a year,  before  it can be sold
in
accordance
     with rule 144.

     During 1998, the Company issued a total of 1,590,278 shares
of
Common Stock
     to  directors  of the  Company.  10,000 of these  shares were
booked at the
     price of the most recent sale of the stock for cash to
shareholders of the
     registration  statement  held  effective  July 28,  1998.
The
balance  of
     1,580,278 was issued in conjunction  with the Waite and See
Agreement,  see
     Notes 8 and 9.

     During 1998, the Company  approved and issued 10,000 shares
of
Common Stock
     (restricted)  to an employee of the Company for prior and
current
services
     rendered.  In addition,  during 1998 the Company  issued
97,500
shares of
     Common Stock for services performed by outside consultants.
270,200 shares
     of Common  Stock were  returned to the Company  treasury as
part
of a legal
     settlement with prior affiliates of the Company (see Note
10).
These shares
     were recorded at the lesser of 1) the value of the Common
Stock on
the date
     issued or 2) the most recent sale of the stock for cash to
shareholders of
     the registration statement held effective July 28, 1998.

     During the first quarter 1999,  the Company  issued 15,000
shares
of Common
     Stock  to an  employee  of  Company,  in  accordance  with
her
employment
     agreement and considered additional  compensation fully
earned in
1998. The
     stock is  restricted as defined in Rule 155 under  Securities
Act
of 1933.
     The employee is no longer with the Company.  The  transaction
was
valued at
     the low bid price on the day of the transfer, or $16,875.

     6. The  Company  often pays for  services,  fees,  and
salaries
by issuing
     shares of Common Stock. Most of this stock issued for
services
must be held
     for  investment to satisfy the exemption  from  registration
under Section
     4(2) of the Securities Act of 1933, as amended.  Rule 144
under
the statute
     requires  that  such  stock  be held for a year,  before  it
can
be sold in
     accordance with rule 144.

     During the first  quarter  2000,  the Company  issued
2,500,000
shares of
     Common Stock to an officers and directors of the Company,  as
authorized by
     the Board of Directors of the Company.  The stock is
restricted
as defined
     in Rule 155 under Securities Act of 1933. These transactions
were
valued at
     $25,000.

                                       8
<PAGE>

NOTE 8 - INCOME TAXES

The  Company  has  federal  net  operating  loss carry  forwards
for
financial
statement purposes of approximately $14,000,000 at December 31,
2000,
which will
be used to offset future  earnings of the Company.  The loss carry
forwards will
expire during the years ending 2002 through 2013 if not used.

NOTE 9 - CONTINGENCIES

The Company is a party in certain  pending or  threatened  legal,
governmental,
administrative,  or judicial  proceedings  that arose in the
ordinary
course of
business.  The  following  includes  a list of  current  pending
or
threatened
proceedings,  which are  believed  not to affect the  financial
position of the
Company in a material way at this time:

1.   Investors Capital  Enterprises,  Inc. v. Harvard  Scientific
Corp.
and Does
     1-50 Case No: BC209049, filed April 20, 1999 in Superior
Court,
Los Angeles
     County, State of California.  Investor's Capital Enterprises,
Inc. alleges
     that it was due a fee of 87,500 shares (post-split) of the
Company's Common
     Stock in exchange for arranging  certain  financing.  The
complaint alleges
     that it did arrange certain  financing  through DJ Ltd.
Investors
Capital
     Enterprises  claims that such an investment  qualifies  for
its
commission
     agreement  and that it advised the Company in writing on July
1,
1996.  The
     complaint  alleges that the market  value of 87,500  shares
on May
15, 1996
     was $2,100,000.

     During  September  1999,  the court ordered this Case to
proceed
to binding
     arbitration.  However, to date, Investors Capital
Enterprises,
Inc. has not
     initiated the arbitration.

2.   RK Company vs. Harvard  Scientific Corp., Case No. 99 C 4261,
United States
     District Court, Northern District of Illinois, Eastern
Division.
Plaintiff
     alleges  massive  fraud  perpetrated  by Defendant  to induce
Plaintiff to
     invest and hold securities in Harvard Scientific.

NOTE 10 - UNCERTAINTY - GOING CONCERN

The financial  statements  of the Company have been  prepared
assuming
that the
Company will continue as a going concern.  The Company's
continued
existence is
dependent  upon its ability to resolve its liquidity  problems,
principally  by
obtaining additional equity capital from other sources. If
additional
capital is
not secured, there is considerable doubt about the Company's
ability to
continue
as a going concern.

ITEM NO. 2. Management's Discussion and Analysis or Plan of
Operation

     MANAGEMENT'S  DISCUSSION  AND  ANALYSIS OF  FINANCIAL
CONDITION
OR PLAN OF
     OPERATION

Some of the discussion contained in this Item 6 and elsewhere in
this
form 10QSB
is "forward looking", as that term is identified in, or
contemplated
by, Section
27A of the  Securities  Act and Section 21E of the  Exchange  Act.
Accordingly,
actual results may materially  differ from  projections or other
indications of
future results.  Information  concerning factors that could cause
actual results
to differ  materially from any projection or other indications of
future results
is  available  in this item 6,  elsewhere in this Form 10Q-SB and
in
the filings
that  the  company  has  made or may  make  with  the  Securities
and
Exchange
Commission in connection  to the Company's  shareholders  or in
news
releases by
the Company.

OVERVIEW:

The Company  entered into a termination  agreement with principals
of
Four Starz
Productions,  Inc., Gladiator Films, Inc., La Playa Studios, Inc.
and
Four Starz
Holdings, Inc. as outlined in the 8K as filed by the Company on
June 8,
2001. In
addition the Company  entered into an Exchange  Agreement with the
principals of
Ragin Cajun International Cafe, Inc., Hollywood  Production
Partners,
Inc. and
The Hollywood  Cinema  Renovation  Project,  Inc. The  agreement
called for the
company to acquire one hundred per cent of the issued and
outstanding
stock of
Ragin Cajun International,  Inc., The Hollywood  production
partners,
Inc. and
fifty one percent of The  Hollywood  Cinema  Renovation  project
in
exchange for
45,000,000 shares of the outstanding stock of Harvard Scientific
Corporation, as
delineated in the Form 8K filed by the company on June 8, 2001.
The
Company may
eventually further develop its biopharmaceutical  products under a
separate name
and  company,  to be  determined  at a later  date.  The focus of
the
Company's
activity  over the next  twelve  months  will be to attempt to
further
develop,
produce and distribute the existing projects in the Company's
recently
acquired
subsidiaries. The Company and its new management are currently in
the
process of
discharging the Company's  outstanding debts, and are actively
negotiating with
its debt  holders to this end.  At the time of this  filing the
Company
has paid
down more than $200,000 of the  outstanding  debt of the Company
through paid in
capital by management. The Company may use cash or Company
securities
to further
discharge  the debt and to the extent funds are required may seek
loans
or stock
purchases  by  third  parties,   the  sale  of  assets  of  the
newly
acquired
subsidiaries or personal loans from the officers and directors of
the
Company.
Included in this quarterly report are operating results for Ragin
Cajun
International, Inc.

The Board of  Directors  of the  Company  consists  of three
members
and may be
increased to seven  members.  The current Board of Directors will
seek
qualified
individuals with solid experience in the entertainment  industry
to
complete the
Board of Directors.

Hollywood  Production  Partners,  Inc. is now a wholly owned
subsidiary  of the
Company.  Daniel De Liege,  a director  and  President  of the
Company,  is the
President of Hollywood production Partners,  Inc. Hollywood
Production
Partners,
Inc. is a producer and funder of feature length motion pictures.

                                       9
<PAGE>

Ragin Cajun  International Cafe, Inc. is now a wholly subsidiary
of the
Company.
Ragin  Cajun  International  Cafe,  Inc.  is a Cajun  themed
restaurant  on Ft.
Lauderdale  Beach Florida and has been in operation  since
December
2000.  The
restaurant  is at the corner of Sunrise  Lane and NE 9th Avenue
and
encompasses
three floors. The restaurant seats 210, has a full liquor licenses
and
a rooftop
bar overlooking the Atlantic Ocean. It is the intention of the
management of the
Company to further  develop the Cajun themed  restaurant  by
opening
additional
locations  in select  cities in the United  States.  The  Company
is
currently
negotiating  a lease for the second  restaurant in Murray,
Kentucky.
It is the
intention of  management to open the second  restaurant  before
the end
of 2001.
Management  intends  to  continue  opening  restaurants  and
possible
begin  a
franchise  program in the near future.  Funding for the second
restaurant  will
come from the  Officers  and  Directors  of the  Company.  The
Company
will seek
outside funds to further develop the Cajun restaurant theme.

The Hollywood Cinema Renovation Project, Inc. is owned fifty one
per
cent by the
Company. The Hollywood Cinema Renovation Project, Inc. is a 20,000
+
square foot
1950's  cinema  located on Young  Circle in  Hollywood,  Florida.
The
property
includes two retail spaces of  approximately  3,500 square feet
each.
One of the
retail spaces has a convenience  store tenant under long-term
lease.
The cinema
and unoccupied  retail space are  undeveloped at the time of this
filing.  It is
the  intention of the  management of the Company to develop the
1200
seat cinema
into a live  performance  theater  complete  with  audio  and
video
broadcast,
mastering and recording capabilities.  The management further
intends
to include
a full  service  restaurant  and full  liquor bar on the  property
to
serve the
theater.  The  property  has a current  appraisal  value of 1.7
million  and an
existing  mortgage of $918,000.  The property will require 4
million
dollars to
completely develop, pay off the existing mortgage and provide
operating
capital.
Management  is seeking  funding from  institutional  and private
investors  and
guarantee can be given as to the success of obtaining required
funds.


Liquidity and Capital Resources:

A Company  officer and major  shareholder  has paid in more than
$200,000  since
June 8,  2001 to reduce  the  Company's  outstanding  debt and
provide
working
capital.  The Company is currently seeking  additional  financing
through loans,
paid in capital or the sale of company assets.

Results of Operations:

During the period  ending September 30, 2001, the  Company  had
sales
of $31,136.25. During that time, the Company has shifted its
focus from strictly  biopharmaceuticals to entertainment.  The
company
has begun
to seek a licensor or purchaser for its medical products.

The Company's total current liabilities for the quarter ending
September 30, 2001 are $182,397.92.

                                     Part II

                                Other Information

ITEM NO. 1. Legal Proceedings

Registrant  incorporates  herein  by this  reference  the
description
of legal
proceedings  contained in the Registrant's Form 10-KSB filed with
the
Securities
and Exchange Commission on April 18, 2001.

ITEM NO. 2. Changes in Securities and Use of Proceeds

Any changes  regarding the  securities or use of proceeds of the
Registrant are
described in the Registrant's Form 10-KSB filed with the
Securities and
Exchange
Commission on April 18, 2001. Such  information is  incorporated
herein by this
reference.

ITEM NO. 3. Defaults Upon Senior Securities

None

ITEM NO. 4. Submission of Matters to a Vote of Security Holders

No matters  have been  submitted to a vote of the  security
holders
during the
period covered by this report through the solicitation of proxies
or
otherwise.

                                       10
<PAGE>

ITEM NO. 5. Other Information

None.

ITEM NO. 6. Exhibits and Reports on Form 8-K

A. Exhibits

(2) Plan of acquisition, reorganization, liquidation or
succession:

NONE.

(3) (i) Articles of Incorporation*
(ii) By-laws*

(27) Financial Data Schedule.

* Incorporated by reference from the Registrant's Form 10-KSB.

B. Reports on Form 8-K

Registrant  incorporates herein by this reference the Registrants
Form
8-K filed
with the  Securities  and  Exchange  Commission  on March 19, 2001
and
April 23,
2001.

                                   Signatures

In  accordance  with  Section 13 or 15(d) of the Exchange  Act,
the
registrant
caused this report to be signed on its behalf by the undersigned,
thereunto duly
authorized.

                            HARVARD SCIENTIFIC CORP.

Name                        Title
Date

/s/ H. N. Higginbotham      Treasurer
- --------------------
    H. N. Higginbotham
    September 30, 2001